Does Cyclosporine Have a Beneficial Effect on the Course of Chronic Hepatitis C Infection After Renal Transplantation?

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1329-1332

  Kamar, N ^a,b   Selves, J ^b   Sandres Saune, K ^b   Durand, D ^a   Izopet, J ^b   Rostaing, L ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS ANTIBODY; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RNA ANALYSIS; SURGICAL PATIENT; VIRUS DETECTION;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 33745222754     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.069     Document Type: Article

References (22)

1. Legendre C., Garrigue V., Le Bihan C., et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65 (1998) 667
2. Mathurin P., Mouquet C., Poynard T., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29 (1999) 257
3. Younossi Z.M., Braun W.E., Protiva D.A., et al. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 67 (1999) 272
4. Zylberberg H., Nalpas B., Carnot F., et al. Severe evolution of chronic hepatitis C in renal transplantation. a case control study. Nephrol Dial Transplant 17 (2002) 129
5. Izopet J., Rostaing L., Sandres K., et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 181 (2000) 852
6. Glicklich D., and Kapoian T. Should the hepatitis C positive end-stage renal disease patients be transplanted?. Semin Dial 9 (1996) 5
7. Rostaing L., Izopet J., Cisterne J.M., et al. Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients. correlation with clinicopathological features. Transplantation 65 (1998) 930
8. Alric L., Di-Martino V., Selves J., et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 123 (2002) 1494
9. Giordano H.M., França A.V.C., Meirelles L., et al. Chronic liver disease in kidney recipients with hepatitis C virus infection. Clin Transplant 17 (2003) 195
10. Bedossa P., Poynard T., and The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996) 289
11. Poynard T., Bedossa P., Opolon P., The OBSVIRC, METAVIR, CLINIVIR, and and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825
12. Poynard T., McHutchison J.G., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303
13. Arthur M.J.P. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122 (2002) 1525
14. Roth D., Reddy K.R., Kupin W., et al. Long-term impact of HCV on clinical outcomes and liver histology in kidney recipients. Am J Transplant A 478 (2004) 289
15. Fehr T., Riehl H.M., Nigg L., et al. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis 42 (2003) 193
16. Watashi K., Hijikata M., Hosaka M., et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38 (2003) 1282
17. Nakagawa M., Sakamoto N., Enomoto N., et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313 (2004) 42
18. Inoue K., Sekiyama K., Yamada M., et al. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C. controlled trial. J Gastroenterol 38 (2003) 567
19. Rimola A., Londono M.C., Guevara G., et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78 (2004) 686
20. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recepients. Am J Transplant 3 (2003) 590
21. Yildiz A., Tutuncu Y., Yazici H., et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation 74 (2002) 1109
22. Finni P.E.S., Souza E.R.M., Rioja S., et al. Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus?. Transplant Proc 36 (2004) 884